Cullinan Associates’s Boston Scientific BSX Stock Holding History

Cullinan Associates’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Buy	24,299 +500	+2%	+$27.1K	0.08%	120
2026 Q1	$1.49M	Buy	23,799 +11,399	+92%	+$912K	0.12%	106
2025 Q4	$1.18M	Hold	12,400	–	–	0.08%	125
2025 Q3	$1.21M	Hold	12,400	–	–	0.08%	125
2025 Q2	$1.33M	Sell	12,400 -13,300	-52%	-$1.35M	0.09%	118
2025 Q1	$2.59M	Sell	25,700 -1,700	-6%	-$171K	0.18%	96
2024 Q4	$2.45M	Sell	27,400 -1,600	-6%	-$141K	0.16%	102
2024 Q3	$2.56M	Buy	29,000 +500	+2%	+$39.4K	0.14%	107
2024 Q2	$2.19M	Hold	28,500	–	–	0.12%	110
2024 Q1	$1.95M	Hold	28,500	–	–	0.11%	119
2023 Q4	$1.65M	Hold	28,500	–	–	0.09%	122
2023 Q3	$1.5M	Hold	28,500	–	–	0.09%	130
2023 Q2	$1.54M	Buy	28,500 +9,500	+50%	+$496K	0.08%	136
2023 Q1	$951K	Sell	19,000 -1,400	-7%	-$66K	0.06%	160
2022 Q4	$944K	Hold	20,400	–	–	0.05%	167
2022 Q3	$790K	Hold	20,400	–	–	0.05%	155
2022 Q2	$760K	Hold	20,400	–	–	0.05%	151
2022 Q1	$904K	Hold	20,400	–	–	0.05%	148
2021 Q4	$867K	Buy	20,400 +15,000	+278%	+$630K	0.04%	147
2021 Q3	$234K	Hold	5,400	–	–	0.01%	216
2021 Q2	$231K	Hold	5,400	–	–	0.01%	210
2021 Q1	$209K	Buy	+5,400	New	+$204K	0.01%	205
2014 Q2	–	Sell	-41,965	Closed	-$567K	–	86
2014 Q1	$567K	Hold	41,965	–	–	0.06%	82
2013 Q4	$504K	Hold	41,965	–	–	0.06%	82
2013 Q3	$492K	Hold	41,965	–	–	0.07%	83
2013 Q2	$389K	Buy	+41,965	New	+$356K	0.05%	84

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cullinan Associates's BSX Position: Q2 2026 in Review

Cullinan Associates increased its Boston Scientific (BSX) stake by 2.1% in Q2 2026, buying an estimated $27.1K and bringing the position to 24,299 shares worth $1.04M. The position accounts for 0.08% of the portfolio, ranked #120.

Cullinan Associates first reported a position in BSX in Q2 2013 and has held it in 26 quarters since. The position peaked at $2.59M in Q1 2025. 1,481 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Cullinan Associates held 24,299 shares of Boston Scientific worth $1.04M as of Q2 2026.
Cullinan Associates bought 500 Boston Scientific shares in Q2 2026, an estimated $27.1K.
Boston Scientific made up 0.08% of Cullinan Associates's portfolio in Q2 2026, its #120 holding.
Cullinan Associates first reported a position in Boston Scientific in Q2 2013 and has held it in 26 quarters since.
Cullinan Associates's Boston Scientific position peaked at $2.59M in Q1 2025.
1,481 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Cullinan Associates's 13F filing for Q2 2026, filed 29 Jul 2026.